secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001562762-23-000405
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q3 revenue $383.6M (+51% YoY); raises FY revenue guidance to $1.55B
--------------------------------------------------------------------------------

- GAAP net income $1.0M, diluted EPS $0.01; non-GAAP diluted EPS $0.57 (+14.7% YoY).
- NuVasive merger closed Sept 1; combined results from that date drove 51% revenue increase.
- Stand-alone Globus Medical net sales $281.2M (+10.7% YoY); U.S. +8.1%, International +25.5%.
- Non-GAAP adjusted EBITDA $112.9M (29.4% of sales); free cash flow $29.0M.
- FY 2023 revenue guidance raised to $1.55B (from $1.125B); non-GAAP EPS reaffirmed at $2.30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/0001562762-23-000405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276223000405/gmed-20231107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-23-000405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer